Validation of the Antioxidant and Enzyme Inhibitory Potential of Selected Triterpenes Using In Vitro and In Silico Studies, and the Evaluation of Their ADMET Properties
The antioxidant and enzyme inhibitory potential of fifteen cycloartane-type triterpenes’ potentials were investigated using different assays. In the phosphomolybdenum method, cycloalpioside D (<b>6</b>) (4.05 mmol TEs/g) showed the highest activity. In 1,1-diphenyl-2-picrylhydrazyl (DPPH...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/db56720169794d9da42b232f005f8f0d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | The antioxidant and enzyme inhibitory potential of fifteen cycloartane-type triterpenes’ potentials were investigated using different assays. In the phosphomolybdenum method, cycloalpioside D (<b>6</b>) (4.05 mmol TEs/g) showed the highest activity. In 1,1-diphenyl-2-picrylhydrazyl (DPPH*) radical and 2,2′-azino-bis(3-ethylbenzothiazoline)-6-sulfonic acid (ABTS) cation radical scavenging assays, cycloorbicoside A-7-monoacetate (<b>2</b>) (5.03 mg TE/g) and cycloorbicoside B (<b>10</b>) (10.60 mg TE/g) displayed the highest activities, respectively. Oleanolic acid (<b>14</b>) (51.45 mg TE/g) and 3-<i>O</i>-β-<span style="font-variant: small-caps;">d</span>-xylopyranoside-(23<i>R</i>,24<i>S</i>)-16β,23;16α,24-diepoxycycloart-25(26)-en-3β,7β-diol 7-monoacetate (<b>4</b>) (13.25 mg TE/g) revealed the highest reducing power in cupric ion-reducing activity (CUPRAC) and ferric-reducing antioxidant power (FRAP) assays, respectively. In metal-chelating activity on ferrous ions, compound <b>2</b> displayed the highest activity estimated by 41.00 mg EDTAE/g (EDTA equivalents/g). The tested triterpenes showed promising AChE and BChE inhibitory potential with 3-<i>O</i>-β-<span style="font-variant: small-caps;">d</span>-xylopyranoside-(23<i>R</i>,24<i>S</i>)-16β,23;16α,24-diepoxycycloart-25(26)-en-3β,7β-diol 2′,3′,4′,7-tetraacetate (<b>3</b>), exhibiting the highest inhibitory activity as estimated from 5.64 and 5.19 mg GALAE/g (galantamine equivalent/g), respectively. Compound <b>2</b> displayed the most potent tyrosinase inhibitory activity (113.24 mg KAE/g (mg kojic acid equivalent/g)). Regarding α-amylase and α-glucosidase inhibition, 3-<i>O</i>-β-<span style="font-variant: small-caps;">d</span>-xylopyranoside-(23<i>R</i>,24<i>S</i>)-16β,23;16α,24-diepoxycycloart-25(26)-en-3β,7β-diol (<b>5</b>) (0.55 mmol ACAE/g) and compound <b>3</b> (25.18 mmol ACAE/g) exerted the highest activities, respectively. In silico studies focused on compounds <b>2</b>, <b>6</b>, and <b>7</b> as inhibitors of tyrosinase revealed that compound <b>2</b> displayed a good ranking score (−7.069 kcal/mole) and also that the ΔG free-binding energy was the highest among the three selected compounds. From the ADMET/TOPKAT prediction, it can be concluded that compounds <b>4</b> and <b>5</b> displayed the best pharmacokinetic and pharmacodynamic behavior, with considerable activity in most of the examined assays. |
|---|